Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

BX795

Home DrugsBX795

BX795

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Application of tyrosine protein kinase JAK2 inhibitor BX795
Applicant: UNIV QINGDAOPriority: 2018
CN
Application of BX795 in preparation of cancer suppressor protein PTEN activator
Applicant: UNIV HANGZHOU NORMALPriority: 2022
CN
Application of BX795 in preparation of medicine for treating chronic myelogenous leukemia
Applicant: UNIV HANGZHOU NORMALPriority: 2022
CN
BX795在制备NK-92细胞激活剂上的应用
Applicant: 杭州师范大学Priority: 2022
CN
Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
Applicant: STCUNMPriority: 2018
US
一种NK细胞的高效基因转导方案
Applicant: 北京景达生物科技有限公司Priority: 2022
CN
一种基于重组腺病毒的CAR-NK细胞制备方法及其应用
Applicant: 北京景达生物科技有限公司Priority: 2023
CN
Method for preparing CAR-NK92 by improving lentivirus infection efficiency of NK92
Applicant: UNIV ZHEJIANG CITY COLLEGEPriority: 2023
CN